Penc drug11/13/2023 If you’re currently taking a citrate-free Humira product (or you’re looking to switch to one), you may have several options.Ĭoncentration. Most Humira biosimilars don’t contain citrate. Your options may be more limited if you need a different dosage. If you’re taking 40 mg, you’ll have several options to choose from. No Humira biosimilars are currently approved for this condition.ĭosage. But if you’re taking Humira for uveitis, you may need to stick with it for now. If you’re taking Humira for HS, certain biosimilars also have this indication. There are a few things to consider when discussing your options with your healthcare provider. So, should you switch to a Humira biosimilar? It depends. ![]() All are low-concentration forms and citrate-free.Ĭyltezo launched on July 1, 2023, making it the first interchangeable Humira biosimilar available in the U.S. Other Humira biosimilars can’t be substituted this way.Ĭyltezo is currently approved as a prefilled pen (40 mg) and syringe (10 mg, 20 mg, and 40 mg). Think of it as substituting a generic for a brand-name medication. Biosimilars without this designation haven’t gone through these same studies.īut what does this mean for people taking these medications? Depending on your state, your pharmacist may be able to dispense Cyltezo for a Humira prescription without contacting your healthcare provider. Interchangeable biosimilars go through additional studies to determine whether you can switch back and forth between the biosimilar and the original product without issues. It’s also a Humira biosimilar approved to treat HS in adults. In October 2021, it also became the first biosimilar to be designated as interchangeable with Humira. AmjevitaĬyltezo (adalimumab-adbm) became the second FDA-approved Humira biosimilar in August 2017. A few biosimilars have high-concentration forms approved or under FDA review. This may make injections easier and faster. Newer Humira products are citrate-free and come in a higher concentration, so they deliver the same amount of medication in a smaller amount of liquid. These products are still available, and most of the biosimilars are based on this original, low-concentration formula. When Humira products were first introduced, they used a formulation that had a relatively low concentration and contained citrate, an ingredient that can make injections more painful. They vary in their available concentrations and doses as well. None of the biosimilars are approved to treat uveitis. And they’re only approved for this use in adults. Some of the biosimilars are approved to treat hidradenitis suppurativa (HS), but not all of them. The Humira biosimilars launching in 2023 are approved for most of the same uses as Humira, with two exceptions. Humira is usually administered once a week or once every other week. It also comes in several different doses, ranging from 10 mg to 80 mg. ![]() ![]() Humira is packaged in three different ways: a prefilled pen, a prefilled syringe, and a vial. Hidradenitis suppurativa (ages 12 and older).Juvenile idiopathic arthritis (ages 2 and older).
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |